Shares of Hillevax Inc (NASDAQ:HLVX) climbed 2.9% after the company revealed it had entered into a definitive merger ...

XOMA Royalty Corporation (NASDAQ:XOMA) has unveiled plans to acquire two biotech firms—HilleVax, Inc. (NASDAQ:HLVX) and LAVA ...

Xoma Royalty has agreed to acquire HilleVax. Emeryville, Calif.-based Xoma plans to begin a tender offer for the Boston vaccine developer by Aug. 18, the biotechnology-royalty aggregator said Monday.

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial programs, HIL-214 and HIL-216, are virus-like particle (VLP) based ...

HilleVax Inc.’s stock cratered 89% early Monday, after the biotech said it would discontinue development of a vaccine against norovirus for infants after a trial missed its main goals.

In Q3 2023, HilleVax announced the closing of an underwritten public offering of 9,200,000 shares of its common stock at a price of $12.50 per share for gross proceeds of $115.0 million.

Matthew Caufield has given his Hold rating due to a combination of factors primarily revolving around the uncertainty of HilleVax, Inc’s norovirus vaccine candidates, HIL-214 and HIL-216. The ...

HilleVax's top line data from the phase 2/3 NEST-IN1 study for the prevention of Norovirus-related gastroenteritis is expected mid-2024. Learn more on HLVX stock here.

The filing shows HilleVax had $124.5 million in cash at the end of 2021. Combined with the IPO cash, the company said it plans to spend about $125 million on clinical development of its norovirus ...

HilleVax' Market & Competition According to a 2021 market research report by Mordor Intelligence, the global market for treating infectious enteritis is forecast to grow at a CAGR of almost 4.9% ...

--HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results from a prespecified immunogenicity analysis of the 203 ...